| Vaccine (49) |  |
| Vaccine (49) | |
#Award-winning innovation revolutionises vaccine production A European union (EU)- funded research project has opened up a radical new era in the world of vaccine discovery and production.
Focused on veterinary vaccines, the project's work has made possible a dramatically faster and more effective route to the creation of vaccines to combat some of the most devastating diseases affecting farm livestock.
The same accelerated route can be used to uncover a vast new range of urgently-needed vaccines for humans as well.
Named PLAPROVA (Plant Production of Vaccines), the project was the successful result of an unprecedented co-funding initiative between the EU and Russia
with Russia matching the#2 million of funding provided by the EU under its 7th Framework Programme.
the PLAPROVA consortium focused on the use of plants proteins to produce vaccines against diseases such as avian flu, bluetongue, foot and mouth disease,
which has revolutionary implications for future vaccine production. It also helped win a major innovation award for the lead researcher.
This triggers the production of proteins which are of potential pharmaceutical interest as the basis for new vaccines.
thus opening up much wider possibilities for genuinely novel vaccines. Previously, the timescale required before results were known for just a single protein meant researchers naturally played safe and tended to produce'biosimilars'
i e. vaccines which replicated already existing ones. It was a situation which discouraged the search for new products.
when dealing with seasonal outbreaks when a vaccine needs to be created urgently, usually in a matter of months from the time the strain of disease is first indentified.
Discussions are in progress with vaccine manufacturers in South africa about production of a bluetongue vaccine. And a Canadian firm, Medicago Inc, has applied successfully the technique to the discovery and production of pandemic flu vaccines for humans, on
which it has completed recently a Phase II clinical trial. The revolutionary impact of the new PLAPROVA technique
with the possibilities it opens up for future work in vaccine discovery, was recognised with the naming of Professor Lomonossoff as Innovator of the Year 2012 by the Biotechnology and Biological sciences Research Council (BBSRC), U s
#Synthetic vaccine could prevent future outbreaks of foot-and-mouth disease Virologists have devised a way to create an entirely synthetic vaccine for foot-and-mouth disease.
The vaccine could prevent future outbreaks of the disease, and potentially lead to new treatments for polio and other human diseases.
and spurred a decision to protect against future outbreaks with vaccination rather than mass slaughter.
however a vaccine made from inactivated virus caused another UK outbreak. The authors say that there is absolutely no chance that their new vaccine could revert into an infectious virus
because it contains no viral genes. Also being entirely synthetic, it cannot be contaminated with live virus during manufacturing.
It will be 6-8 years before the vaccine is available to farmers, they estimate. But if the method used to create the vaccine proves successful when scaled to commercial production,
it could also be used to create vaccines for human diseases that are caused by viruses of the same family, such as hand, foot and mouth disease,
which is ubiquitous in Southeast asia, and polio, which still blights the lives of millions of people in the developing world."
But if we could use this to move away from inactivated polio viruses in the vaccines,
Earlier attempts to produce a synthetic vaccine for foot and mouth disease were thwarted often by peculiarities of viral geometry.
The team got around the problem by engineering the vaccine to have disulphide bonds cross-linking the protein triangles together.
and Charleston that the new vaccine is unable to cause an infection or outbreak. Marvin Grubman, an animal-disease researcher at the US Department of agriculture in Orient Point, New york, says that the new vaccine"is a good piece of work,
but certainly not very novel, pointing to a foot-and-mouth vaccine his team devised that uses adenovirus to deliver empty viral shells.
That vaccine, he says, has been approved for use in the United states for cases of emergency. The authors however point out that their vaccine does not require the injection of live viruses
and that it would be suitable for preventive vaccination as well as in cases of severe outbreaks o
#Gene-analysis firms reach for the cloud For Chaim Jalas at the Center for Rare Jewish Genetic disorders in New york,
DNA sequencing is the easy part. It costs less than US$1, 500 per person to have the important parts of his clients genomes sequenced.
who are demonstrating delivery of vaccines in Africa. Delta Drone in France is using the platform for open-air mining operations,
#Ebola Vaccine Demonstrates 100%Protection in Latest African Trial According to an unusual new study, published last week in the world most prestigious medical journal Lancet, the deadly outbreak
might finally come to an end a vaccine, developed by the Public health Agency of Canada and manufactured by the American pharmaceutical company Merck Sharp & Dome, was shown just to confer 100%protection against the disease,
One of the two currently-tested Ebola vaccines has been shown in a recent trial to provide 100%protection against the disease
who wasn involved in the study. e will teach about this in public health schools. he vaccine,
the researchers opted for a design called ring vaccination, whereby only the contacts, and the contactscontacts, of new Ebola patients were vaccinated.
This type of approach has never been used in a formal vaccine study ever before. The rings, also called clusters, were randomized such that 48 of them received the vaccine right after a new Ebola case sprung up in their community,
while the other 42 received a shot only three weeks afterwards. Of the 2, 380 people who were assigned to the latter group,
16 got infected. In the second group consisting of 2 014 people the count of new Ebola cases was zero,
The Director-General of THE WHO Margaret Chan called for further studies to clear up any lingering doubts about the vaccine efficacy,
and vaccination tracking campaigns in resource-poor and field settings. In addition to serving low-resource or remote areas, the researchers noted that intrinsic wireless connectivity can serve epidemic-related studies,
or tracking vaccination campaigns in most resource-poor settings. It fantastic for an undergrad to be first author on the publication.
or tracking vaccination campaigns in most resource-poor settings. It fantastic for an undergrad to be first author on the publication.
#World First Malaria Vaccine Approved and it Will be Not-for-Profit The world first malaria vaccine has been given approval by a European medical agency for future use in Sub-saharan africa, where more than a quarter million children under the age of five die every year from the disease.
European regulators examined phase III clinical trial results involving more than 16,000 young children conducted by research centers in eight African countries (Burkina faso, Gabon, Ghana, Kenya, Malawi, Mozambique, Nigeria
Glaxosmithkline Vice president for Africa told CNN. t is the first time anyone ever has been able to make a vaccine against a parasite.
Perhaps most impressive, Glaxosmithkline, the pharmaceutical company that worked on this vaccine for 30 years, and received $200 million from the Gates Foundation, is making RTS, S available as a nonprofit drug.
with all that money going back into further research for a malaria vaccine that could be even more effective.
and expects to invest a further $200 to $250 million until the vaccine is ready for market.
With this approval from the European Medicines Agency Friday, the vaccine next will be considered by the World health organizations,
and if they will use the vaccine, along with current Malaria prevention techniques, like bed nets. 80%of the children involved in the clinical trials were protected also by insecticide treated bed nets.
malaria cases were reduced by almost half in children aged 5-17 months at the time of first vaccination and by 27%in infants aged 6-12 weeks.
000 clinical malaria cases were prevented over the study period for every 1, 000 children vaccinated
as a result of an infection and those triggered by a vaccine. Instead the technique might be useful in outbreaks of new viruses. Understanding how our immune system responds to other viral fragments might reveal clues as to
< Back - Next >
Overtext Web Module V3.0 Alpha
Copyright Semantic-Knowledge, 1994-2011